Cite

HARVARD Citation

    Dhakal, P. et al. (2020). Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. Leukemia & lymphoma. 61 (1), pp. 7-17. [Online]. 
  
Back to record